Evidence map›Paper›PMID 38279062›Full record

ArticleOncogene2024

HJURP is recruited to double-strand break sites and facilitates DNA repair by promoting chromatin reorganization.

Rodolfo B Serafim, Cibele Cardoso, Camila B Storti, Patrick da Silva, Hongyun Qi, Ramya Parasuram, Geovana Navegante, Jean Pierre S Peron, Wilson A Silva, Enilza M Espreafico and 3 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Rodolfo B SerafimDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Cibele CardosoDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Camila B StortiDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Patrick da SilvaDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Hongyun QiDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Ramya ParasuramDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Geovana NaveganteSão Paulo State University (UNESP), School of Pharmaceutical Sciences, Rodovia Araraquara - Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP, 14800-903, Brazil.
Jean Pierre S PeronDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0003-1638-8866
Wilson A SilvaCenter for Cell-Based Therapy-CEPID/FAPESP, Rua Tenente Catão Roxo, 2501, Ribeirão Preto, 14051-140, Brazil.ORCID 0000-0001-9364-2886
Enilza M EspreaficoDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Maria L Paçó-LarsonDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Brendan D PriceDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. brendanp999@gmail.com.
Valeria ValenteDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil. valeria.valente@unesp.br.
Universidade de São Paulo · BRDana-Farber Cancer Institute · USCentro Universitário de Araraquara · BRVale (Brazil) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HJURP is overexpressed in several cancer types and strongly correlates with patient survival. However, the mechanistic basis underlying the association of HJURP with cancer aggressiveness is not well understood. HJURP promotes the loading of the histone H3 variant, CENP-A, at the centromeric chromatin, epigenetically defining the centromeres and supporting proper chromosome segregation. In addition, HJURP is associated with DNA repair but its function in this process is still scarcely explored. Here, we demonstrate that HJURP is recruited to DSBs through a mechanism requiring chromatin PARylation and promotes epigenetic alterations that favor the execution of DNA repair. Incorporation of HJURP at DSBs promotes turnover of H3K9me3 and HP1, facilitating DNA damage signaling and DSB repair. Moreover, HJURP overexpression in glioma cell lines also affected global structure of heterochromatin independently of DNA damage induction, promoting genome-wide reorganization and assisting DNA damage response. HJURP overexpression therefore extensively alters DNA damage signaling and DSB repair, and also increases radioresistance of glioma cells. Importantly, HJURP expression levels in tumors are also associated with poor response of patients to radiation. Thus, our results enlarge the understanding of HJURP involvement in DNA repair and highlight it as a promising target for the development of adjuvant therapies that sensitize tumor cells to irradiation.

Indexed as

ChromatinGliomaCentromereCentromere Protein AChromosomal Proteins, Non-HistoneDNA-Binding ProteinsDNA RepairHumansCentromere Protein AChromatinChromosomal Proteins, Non-HistoneDNA-Binding ProteinsHJURP protein, human

Identifiers

PMID38279062
OpenAlexW4391263002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.